医学と薬学　81/1　2024年1月号

出版社： 自然科学社
発行日： 2023-12-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 腎代替療法
電子書籍版： 2023-12-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

購入する

目次

  • 特集　腎代替療法

    序文
    腎代替療法としての血液透析
    血液透析濾過―オンラインHDFとI-HDF―
    腹膜透析
    腹膜透析＋血液透析併用療法
    腎移植 東邦大学医学部腎臓学講座
    小児の腎代替療法
    透析患者と新型コロナウイルス感染症

    研究
    　若年者で新型コロナウイルス感染後に長引く症状の特徴

    Diagnosis
    　RAbのカットオフ値近傍における新規TSAb測定試薬
    　　バイオセンサTSAb「ヤマサ」の陽性率の検討

    Cosmetic
    　コラーゲン含有フェイスマスク
    　「ALLUDEMダーマリフトマスク」の使用による加齢肌の改善効果
    　　―ハーフフェイス法を用いた単盲検対照試験―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 腎代替療法】

P.9 掲載の参考文献
1) Lorenzo V, Martn M, Rufino M, et al: Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients: an observational cohort study. Am J Kidney Dis 43:999-1007, 2004.
 
2) Kim JC, Shapiro BB, Zhang M, et al: Daily physical activity and physical function in adult maintenance hemodialysis patients. J Cachexia Sarcopenia Muscle 5:209-220, 2014.
PubMed
3) Kjellstrand CM, Buoncristiani U, Ting G, et al: Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant 23:3283-3289, 2008.
PubMed
P.17 掲載の参考文献
1) Leypoldt JK: Solute fluxes in different treatment modalities. Nephrol Dial Transplant 15(Suppl 1): 3-9, 2000.
 
2) 道脇宏行:オンラインHDFにおける前希釈法と後希釈法の特徴. 日血浄化技会誌 31:23-27, 2023.
 
3) Sakurai K: Biomarkers for evaluation of clinical outcomes of hemodiafiltration. Blood purification 35(Suppl 1):64-68, 2013.
 
4) Grooteman MP, van den Dorpel MA, Bots ML, et al; CONTRAST Investigators: Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes. J Am Soc Nephrol 23:1087-1096, 2012.
PubMed
5) Maduell F, Moreso F, Pons M, et al: ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24:487-97. 2013.
 
6) Ok E, Asci G, Toz H, et al: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 28:192-202, 2013.
PubMed
7) Kikuchi K, Hamano T, Wada A, et al: Predilution online hemodiafiltration is associated with improved survival compared with hemodialysis. Kidney International 95:929-938, 2019.
PubMed
8) 長沼俊秀, 武本佳昭, 鎌田直博, 他:他施設共同HDコホート研究「透析患者におけるα1-midroglobulin除去率が生存・合併症予後に与える影響の検討:JAMREDS-Study」の進捗状況報告 2021. 腎と透析 Vol.93 別冊 HDF療法 '22:11-13, 2022.
 
9) 江口圭, 池辺宗三人, 金野好恵, 他:新しいHDF療法(間歇補液HDF:intermittent infusion HDF)の考案とその臨床効果. 透析会誌 40:769-774, 2007.
 
P.27 掲載の参考文献
1) Zakaria el-R, Carlsson O, Rippe B: Limitation of small-solute exchange across the visceral peritoneum: effects of vibration. Perit Dial Int 17:72-79, 1997.
PubMed
2) Flessner MF: Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol 2:122-135, 1991.
PubMed
3) Mactier RA, Khanna R, Twardowski Z, et al: Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 80:1311-1316, 1987.
PubMed
4) Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al: Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 50:979-986, 1996.
PubMed
5) 日本透析医学会, 腹膜透析ガイドライン改訂ワーキンググループ(編):日本透析医学会ブックシリーズ1 腹膜透析ガイドライン, 医学図書出版, 東京, 2019.
 
6) Lo WK, Bargman JM, Burkart J, et al: Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 26:520-522, 2006.
PubMed
7) Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 12:2158-2162, 2001.
PubMed
8) Paniagua R, Amato D, Vonesh E, et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307-1320, 2002.
PubMed
9) Koh ES, Lee K, Kim SH, et al: Serum β2-Microglobulin Predicts Mortality in Peritoneal Dialysis Patients: A Prospective Cohort Study. Am J Nephrol 42:91-98, 2015.
 
10) Cheung AK, Rocco MV, Yan G, et al: Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 17:546-555, 2006.
PubMed
11) Szeto CC, Kwan BC, Chow KM, et al: Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 35:180-188, 2015.
PubMed
12) McCafferty K, Fan S, Davenport A: Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 85:151-157, 2014.
 
13) Ito M, Saka Y, Kuroki Y, et al: Assessment of the effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis patients: a systematic review and meta-analysis on clinical trials. Ren Replace Ther 5:42, 2019.
 
14) Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59:1128-1133, 2001.
PubMed
15) Ito Y, Mizuno M, Suzuki Y, et al: Nagoya Spiro Study Group. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 25:1094-1102, 2014.
 
16) Hasegawa T, Nishiwaki H, Ota E, et al: Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2:CD013109, 2021.
PubMed
17) Murashima M, Hamano T, Abe M, et al: Combination of once-weekly haemodialysis with peritoneal dialysis is associated with lower mortality compared with peritoneal dialysis alone: a longitudinal study Clin Kidney J 14:1610-1617, 2020.
 
18) Elsurer R, Afsar B, Sezer S, et al: Peritoneal albumin leakage: 2 year prospective cardiovascular event occurrence and patient survival analysis. Nephrology (Carlton) 14:712-715, 2009.
PubMed
19) Li PK, Chow KM, Cho Y, et al: ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42:110-153, 2022.
PubMed
20) Boudville N, Kemp A, Clayton P, et al: Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 23:1398-1405, 2012.
PubMed
21) Mizuno M, Ito Y, Suzuki Y, et al: Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry. Clin Exp Nephrol 20:960-971, 2016.
PubMed
22) Kinashi H, Ito Y, Mizuno M, Suzuki Y, et al: TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol 24:1627-1642, 2013.
 
23) Tawada M, Ito Y, Hamada C, et al: Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients. PLoS One 11:e0154644, 2016.
PubMed
24) Tawada M, Ito Y, Banshodani M, et al: Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions. Nephrol Dial Transplant 36:1519-1526, 2021.
PubMed
25) Szeto CC, Li PK, Johnson DW, et al: ISPD Catheter-Related Infection Recommendations: 2017 Update. Perit Dial Int 37:141-154. 2017.
PubMed
26) Asai A, Kinashi H, Suzuki Y, et al: Safety and utility of the alpha-replacer for treatment of intraluminal obstruction of peritoneal catheters by fibrin clots. Clin Exp Nephrol 25:418-427, 2021.
PubMed
27) Kawanishi H, Kawaguchi Y, Fukui H, et al: Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 44:729-737, 2004.
PubMed
28) Nakayama M, Miyazaki M, Honda K, et al: Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int 34:766-774, 2014.
PubMed
29) Tawada M, Hamada C, Suzuki Y, et al: Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients. Clin Exp Nephro 23:689-699, 2019.
 
P.31 掲載の参考文献
1) 日本透析医学会:わが国の慢性透析療法の現況. (2021年12月31日現在) https://docs.jsdt.or.jp/overview/file/2021/pdf/2021all.pdf?20230306
 
2) Matsuo N, Yokoyama K, Tanno Y, et al: Combined therapy using peritoneal dialysis and hemodialysis may increase the indications for peritoneal dialysis in the United States. Kidney Int 87:1259-1260, 2015.
PubMed
P.38 掲載の参考文献
1) Tonelli M, Wiebe N, Knoll G, et al: Systematic review: kidney transplantation compared to dialysis in clinically relevant outcomes. Am J Transplant 11:2093-2109, 2011.
PubMed
2) Davison JM: Dialysis, transplantation, and pregnancy, Am J Kidney Dis 17:127-132, 1991.
PubMed
3) 日本移植学会:ファクトブック2022. http://www.asas.or.jp/jst/pdf/factbook/factbook2022.pdf
 
4) Global Observatory on Donation and Transplantation (GODT): INTERNATIONAL REPORT ON Organ Donation and Transplantation Activities 2021. https://www.transplant-observatory.org/wp-content/uploads/2022/12/2021-data-global-report-1.pdf
 
5) IRODaT: DATABASE, WORLDWIDE ACTUAL DECEASED ORGAN DONORS 2021. https://www.irodat.org/?p=database
 
6) 日本臨床腎移植学会・日本移植学会:腎移植臨床登録集計報告(2022)2021年実施症例の集計報告と追跡調査結果. 移植 57:199-219, 2022.
Medical*Online
7) 日本移植学会:生体腎移植ガイドライン. http://www.asas.or.jp/jst/pdf/guideline_002jinishoku.pdf
 
8) Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Transplant Candidate Work Group: KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation 104:S1-S103, 2020.
 
9) 日本腎臓学会, 日本透析医学会, 日本腹膜透析医学会, 他:腎代替療法選択ガイド2020. ライフサイエンス出版, 東京, 2020.
 
10) 日本臨床腎移植学会:生体腎移植ドナーガイドライン. http://www.asas.or.jp/jst/pdf/manual/008.pdf
 
11) 日本透析医学会:わが国の慢性透析療法の現況, 2021年末の慢性透析患者に関する集計. https://docs.jsdt.or.jp/overview/file/2021/pdf/2021all.pdf?20230306
 
12) Loupy A, Haas M, Roufosse C, et al: The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20:2318-2331, 2020.
 
13) Sellares J, de Freitas DG, Mengel M, et al: Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Trasnplant 12:388-399, 2012.
 
14) Briganti EM, Russ GR, McNeil JJ, et al: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347:103-109, 2002.
PubMed
15) Allen PJ, Chadban SJ, Craig JC, et al: Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int 92:461-469, 2017.
PubMed
16) Choy BY, Chan TM, Lai KN:Recurrent glomerulonephritis after kidney transplantation. Am J Tranaplant 11:2535-2542, 2006.
 
17) Cheung CY, Tang SCW:An update on cancer after kidney transplantation. Nephrol Dial Trasnplant 34:914-920, 2019.
 
18) Maisonneuve P, Agodoa L, Gellert R, et al: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93-99, 1999.
PubMed
19) Kasiske BL, Guijarro C, Massy ZA, et al: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996.
PubMed
20) Agrawal A, Ison MG, Danziger-Isakov L: Long-Term Infectious Complications of Kidney Transplantation. Clin J Am Soc Nephrol 17:286-295, 2022.
PubMed
21) Kasiske BL, Anjum S, Shah R, et al: Hypertension after kidney transplantation. Am J Kidney Dis 43:1071-1081, 2004.
PubMed
22) Cross NB, Webster AC, Masson P, et al: Anti-hypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 3:CD003598, 2009.
 
23) 日本臨床腎移植学会(編):腎移植後内科・小児科系合併症の診療ガイドライン2011, 日本医学館, 東京, 2011.
 
24) Jenssen T, Hartmann A: Post-transplant diabetes mellitus with solid organ transplants. Nat Rev Endocrinol 15:172-188, 2019.
PubMed
25) Okumi M, Unagami K, Hirai T, et al: Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study. Int J Urol 24:197-204, 2017.
 
26) Valderhaug TG, Hjelmesaeth J, Hartmann A, et al: The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54:1341-1349, 2011.
PubMed
27) Vincenti F, Friman S, Scheuermann E, et al: Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcomes with Cyclosporin Versus Tacrolimus. Am J Transplant 7:1506-1514, 2007.
PubMed
28) Navaneethan SD, Perkovic V, Johnson DW, et al: HMG-CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Sys Rev 2:CD005019, 2009.
 
29) Murakami N, Riella LV, Funakoshi T: Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 14:2317-2327, 2014.
PubMed
30) Imoagene-Oyedeji AE, Rosas SE, Doyle AM, et al: Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. Am J Soc Nephrol 17:3240-3247, 2006.
 
31) Kamar N, Rostaing L, Ignace S, et al: Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis. Clin Transplant 26:461-469, 2012.
PubMed
32) Tsujita M, Kosugi T, Goto N, et al: The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 34:1409-1416, 2019.
PubMed
33) Li H, Hu SM, Li YM, et al: Beneficial effect of roxadustat on early posttransplant anemia and iron utilization in kidney transplant recipients: a retrospective comparative cohort study. Ann Transl Med 10:1360, 2022.
PubMed
34) de Oliveira CM, Moura AE, Goncalves L, et al: Post-transplantation weight gain: prevalence and the impact of steroid-free therapy. Transplant Proc 46:1735-1740, 2014.
PubMed
35) Kwan JM, Hajjiri Z, Metwally A, et al: Effect of the Obesity Epidemic on Kidney Transplantation: Obesity Is Independent of Diabetes as a Risk Factor for Adverse Renal Transplant Outcomes. PLoS One 11:e0165712, 2016.
PubMed
P.52 掲載の参考文献
1) 服部元史:小児患者に対する透析. 透析療法合同専門委員会(企画・編集):血液浄化療法ハンドブック2023, 協同医書出版社, pp.263-280, 2023.
 
2) Hattori M, Sako M, Kaneko T et al: End-stage renal disease in Japanese children: a nationwide survey during 2006-2011. Clin Exp Nephrol 19:933-938, 2015.
 
3) Harambat J, van Stralen KJ, Kim JJ et al: Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363-373, 2012.
PubMed
4) 服部元史, 五十嵐隆:統計調査委員会設立の経緯と活動状況に関する報告. 日児腎誌 22:222-225, 2009
 
5) 日本透析医学会:維持血液透析ガイドライン:血液透析導入. 透析会誌 46:1107-1155, 2013.
 
6) 日本透析医学会:透析の開始と継続に関する意思決定プロセスについての提言. 透析会誌 53:173-217, 2020.
 
7) 宍戸清一郎, 服部元史, 相川厚, 他:本邦における小児への献腎配分政策と献腎移植. 日臨腎移植会誌 8:94-100, 2020.
 
8) 服部元史, 三重野牧子, 相川厚, 他:本邦小児腎移植の臨床的背景と移植成績:2016年報告のアップデート. 日臨腎移植会誌 9:215-225, 2021.
 
9) 服部元史:腎移植と小児慢性腎不全診療. 日腎会誌 47:17-25, 2005.
 
10) 宍戸清一郎:小児腎移植における血行再建術. 今日の移植 27:487-494, 2014.
Medical*Online
11) Dharnidharka VR, Fiorina P, Harmon WE: Kidney transplantation in children. N Engl J Med 371:549-558, 2014.
PubMed
12) Van Arendonk KJ, Boyarsky BJ, Orandi BJ, et al: National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics 133:594-601, 2014.
PubMed
13) 高橋公太:ABO血液型不適合腎移植への挑戦-免疫学的禁忌の克服と臨床応用の普及-. 日臨腎移植会誌 1:3-16, 2013.
 
14) Mamode N, Marks SD: Maximizing living donation with paediatric blood-group-incompatible renal transplantation. Pediatr Nephrol 28:1037-1040, 2013.
 
15) Hattori M, Mieno M, Shishido S, et al: Outcomes of pediatric ABO-incompatible living kidney transplantations from 2002 to 2015: An analysis of the Japanese Kidney Transplant Registry. Transplantation 102:1934-1942, 2018.
PubMed
16) 宍戸清一郎, 川村毅, 濱崎祐子:小児をドナーとする献腎移植. 日臨腎移植会誌 9:1-8, 2021.
 
17) 服部元史:小児末期腎不全診療の歩みと現況. 透析会誌 42:137-144, 2009.
 
18) Francis A, Johnson DW, Melk A, et al: Survival after kidney transplantation during childhood and adolescence. Clin J Am Soc Nephrol 15:392-400, 2020.
PubMed
19) Chua A, Cramer C, Moudgil A, et al: Kidney transplant practice patterns and outcome benchmarks over 30 years: The 2018 report of the NAPRTCS. Pediatr Transplant 23:e13597, 2019.
PubMed
20) Yabuuchi T, Miura K, Shimizu S, et al: Cancer after pediatric kidney transplantation: A long-term single-center experience in Japan. Transplant Direct 7:e687, 2021.
PubMed
21) Mumhord L, Maxwell H, Ahmad N, et al: The impact of changing practice on improved outcomes of Paediatric renal transplantation in the United Kingdom: a 25 years review. Transplant Int 32:751-761, 2019.
 
22) 服部元史:難治性ネフローゼ症候群 巣状分節性糸球体硬化症FSGSの臨床, 東京医学社, 2023.
 
23) Dacidovits M, Reisman L, Cleper R, et al: Long-term outcomes during 37 years of pediatric kidney transplantation: a cohort study comparing ethnic groups. Pediatr Nephrol 36:1881-1888, 2021.
 
24) 成田一衛(監), 服部元史・岩野正之(編):思春期・青年期の患者のための末期腎不全(ESKD)診療ガイド, 東京医学社, 2023.
 
25) Hirano D, Inoue E, Sako M et al: Survival analysis among pediatric patients receiving kidney replacement therapy; a Japanese nationwide cohort study. Pediatr Nephrol 38:261-267, 2023.
 
26) Rees L, Hattori M, Borzych-Duzalka D: Infant dialysis. In Emma F, Goldstein SL, Bagga A, et al (eds): Pediatric Nephrology 8th ed., Springer, 2022.
 
27) Miura K, Hattori M, Iwano M, et al: edical and psychosocial outcomes in adolescents and young adults with childhood-onset end-stage kidney disease: a multicenter study in Japan. Clin Exp Nephrol 27:454-464, 2023.
 
28) Miura K, Hattori M, Iwano M, et al: Depression and health-related quality of life in adolescents and young adults with childhood-onset end-stage kidney disease: a multicenter study in Japan. Clin Exp Nephrol 27:473-479, 2023.
 
P.60 掲載の参考文献
1) 日本透析医会・日本透析医学会・日本腎臓学会 新型コロナウイルス感染対策合同委員会(委員長:菊地勘):新型コロナウイルス5類移行後の無症状・軽症患者の外来透析を行う際の隔離透析期間等の考え方について. https://jsn.or.jp/medic/data/COVID-19_info20230427.pdf
 
2) 日本透析医会「透析施設における標準的な透析操作と感染予防に関するガイドライン」改訂に向けたワーキンググループ:透析施設における標準的な透析操作と感染予防に関するガイドライン(五訂版). http://www.touseki-ikai.or.jp/htm/07_manual/doc/20200430_infection%20control_guideline.pdf
 
3) Kikuchi K, Nangaku M, Ryuzaki M, et al: COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. Ther Apher Dial 27:19-23, 2023
 
4) Wing S, Thomas D, Balamchi S, et al: Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period. Clin J Am Soc Nephrol 18:491-498, 2023.
PubMed
5) Quiroga B, Soler MJ, Ortiz A, et al: Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. Nephrol Dial Transplant 38:969-981, 2023.
PubMed
6) Aiswarya D, Arumugam V, Dineshkumar T, et al: Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. Kidney Int Rep 6:586-593, 2021.
PubMed
7) Kikuchi K, Nangaku M, Ryuzaki M, et al, and COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Survival and Predictive Factors in Dialysis Patients with COVID-19 in Japan: A Nationwide Cohort Study. Ren Replace Ther 7:59, 2021.
PubMed
8) Kikuchi K, Nangaku M, Ryuzaki M, et al; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology: Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic. Ther Apher Dial 27:1064-1069, 2023.
PubMed
9) Chang YC, Chen YC, Huang CC, et al: Clinical effectiveness of molnupiravir in COVID-19 patients undergoing hemodialysis. Int J Antimicrob 62:106834, 2023
 

【研究】

P.72 掲載の参考文献
1) 風間逸郎, 佐藤憲治, 吉川陽大, 他:新型コロナウイルス感染の第7波と8波で陽性となった若年者の症状の特徴. 医学と薬学 80:491-497, 2023.
Medical*Online
2) 風間逸郎, 佐藤憲治, 齊藤泰功, 他:【よりよい看護を探究する様々な視点】(Part 3)看護研究 新型コロナウイルス陽性の若年者における第6波と第7波での症状の比較. 看護技術 68:1331-1336, 2022.
 
3) 西野拓人, 風間逸郎:宮城県で発生した新型コロナウイルス感染症患者の特徴 第1波88名の集計から見えた問題点と今後の課題. 宮城大学研究ジャーナル 1:183-201, 2021.
 
4) 寺澤佳洋:【Long COVIDのケア & キュア】総合診療医の視点から"COVID-19罹患後症状"について『新型コロナウイルス感染症(COVID-19)診療の手引き 別冊罹患後症状のマネジメント・第1.1版』を解説する. Tehamo 2:25-29, 2022.
 
5) Kazama I: Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog. Neurochem Res 48:2345-2349, 2023.
PubMed
6) Antonelli M, Pujol J C, Spector T D, et al: Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 399:2263-2264, 2022.
PubMed
7) 相澤美里, 藤倉邑圭, 平井菜々美, 他:若年者で新型コロナワクチン3回目接種後に起きる副反応の特徴 2回目接種後との比較. 医学と薬学 79:1499-1509, 2022.
Medical*Online
8) Kazama I: Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy? Drug Discov Ther 14:143-144, 2020.
PubMed
9) Kazama I, Senzaki M: Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects? Drug Discov Ther 15:278-280, 2021.
PubMed
10) Kazama I: Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease. Inflamm Res 71:1123-1126, 2022.
PubMed
11) Kazama I: Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther 14:259-261, 2020.
PubMed
12) Liu C, Wu X, Vulugundam G, et al: Exercise Promotes Tissue Regeneration: Mechanisms Involved and Therapeutic Scope. Sports Med Open 9:27, 2023.
PubMed
13) Langley M R, Triplet E, M.Scarisbrick I A: Dietary influence on central nervous system myelin production, injury, and regeneration, Biochim Biophys Acta Mol Basis Dis 1866:165779, 2020.
PubMed
14) Byambasuren O, Stehlik P, Clark J, et al: Effect of covid-19 vaccination on long covid: systematic review. BMJ Med 2:e000385, 2023.
PubMed

【Diagnosis】

P.85 掲載の参考文献
1) Adams DD, Purves HD: Abnormal responses in the assay of thyrotropin. Proc Univ Otago Med Sch 34:11-12, 1956.
 
2) Adams DD: Bioassay of long-acting thyroid stimulator (L.A.T.S.); the dose-response relationship. J Clin Endocrinol Metab 21:799-805, 1961.
 
3) Kriss JP, Pleshakov V, Chien JR: Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J Clin Endocrinol Metab 24:1005-1028, 1964.
 
4) Adams DD, Kennedy TH: Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland. J Clin Endocrinol Metab 27:173-177, 1967.
PubMed
5) Shishiba Y, Shimizu T, Yoshimura S, Shizume K: Direct evidence for human thyroidal stimulation by LATS-protector. J Clin Endocrinol Metab 36:517-521, 1973.
PubMed
6) Adams DD, Fastier FN, Howie JB, et al: Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab 39:826-832, 1974.
PubMed
7) Smith BR, Hall R: Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 2:427-431, 1974.
PubMed
8) Endo K, Borges M, Amir S, et al: Preparation of 125I- labeled receptor-purified Graves' immunoglobulins: properties of their binding to human thyroid membranes. J Clin Endocrinol Metab 55:566-576, 1982.
PubMed
9) Shewring G, Smith BR: An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol (Oxf) 17:409-417, 1982.
PubMed
10) Costagliola S, Morgenthaler NG, Hoermann R, et al: Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 84:90-97, 1999.
PubMed
11) Sanders J, Oda Y, Roberts S, et al: The interaction of TSH receptor autoantibodies with 125 I-labelled TSH receptor. J Clin Endocrinol Metab 84:3797-3802, 1999.
 
12) Smith BR, Bolton J, Young S, et al: A new assay for thyrotropin receptor autoantibodies. Thyroid 14:830-835, 2004.
 
13) Tozzoli R, Kodermaz G, Villalta D, et al. Accuracy of receptor-based methods for detection of thyrotropin-receptor autoantibodies: a new automated third-generation immunoassay shows higher analytical and clinical sensitivity for the differential diagnosis of hyperthyroidism. Auto Immun Highlights 1:95-100, 2010.
PubMed
14) Levey GS, Pastan I: Activation of thyroid adenyl cyclase by long-acting thyroid stimulator. Life Sci I 9:67-73, 1970.
PubMed
15) Onaya T, Kotani M, Yamada T, et al: New in vitro tests to detect the thyroid stimulator in sera from hyperthyroid patients by measuring colloid droplet formation and cyclic AMP in human thyroid slices. J Clin Endocrinol Metab 36:859-866, 1973.
PubMed
16) Orgiazzi J, Williams E.D, Chopra JI, et al: Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease. J Clin Endocrinol Metab 42:341-354, 1976.
 
17) 田上哲也, 保科元気, 尾島汐海, 他:次世代迅速TSAb測定法の開発:測定原理と基礎性能～臨床評価. 特集/甲状腺臨床update. 新しいTSAb測定法. 糖尿病・内分泌代謝科 53:479-486, 2021.
 
18) 保科元気, 尾島汐海, 土居耕介, 他:cAMPバイオセンサおよびヒトTSH受容体共発現細胞を用いた新規TSAb測定試薬バイオセンサTSAb「ヤマサ」の基礎的検討. 医学と薬学 79:1079-1086, 2022.
Medical*Online
19) 田上哲也, 吉村弘, 保科元気, 他:cAMPバイオセンサおよびヒトTSH受容体共発現細胞を用いた新規TSAb測定試薬バイオセンサTSAb「ヤマサ」の臨床評価. 医学と薬学 79:1087-1095, 2022.
Medical*Online
20) 上條佳一, 保科元気, 土居耕介, 他:バイオセンサTSAb「ヤマサ」の基礎的・臨床的検討. 医学と薬学 79:1199-1207, 2022.
 
21) 笠木寛治, 蛭間真梨乃, 渡邊奈津子, 他:TSBAb測定の臨床的有用性と限界-改良法ヤマサキットの使用経験-. 日本甲状腺学会雑誌 9:172-179, 2018.
Medical*Online
22) Tagami T, Moriyama K: Characterization of apparently paradoxical thyrotropin binding inhibitory immunoglobulins with neutral bioactivity. J Endocr Soc 6:1-10, 2022.
 
23) Tagami T, Hiroshima-Hamanaka K, Umakoshi H, et al: Experimental reproduction of dynamic fluctuation of TSH receptor-binding antibodies between stimulation and inhibition. J Endocr Soc 3:2361-2373, 2019.
PubMed

【Cosmetic】

P.94 掲載の参考文献
1) 原田彩子, 西原羽衣子:@cosmeからみた, 新しい日常における生活者の美容意識の変化. 日本香粧品学会誌 46:141-147, 2022.
 
2) 藤田雅夫:12. マスクと化粧. 繊維製品消費科学 62:355-360, 2021.
 
3) 宮本久喜三:マスク肌:コロナ禍におけるマスク着用による皮膚への影響を調べるため日内変化を定量的に測定した臨床的調査について. Cosmetic stage/技術情報協会 編 16:19-22, 2022.
 
4) 鈴木公啓, 矢澤美香子:コロナ禍のマスク着用に伴う化粧行動の変化はどのような心理的影響を及ぼすか. 容装心理学研究 1:5-12, 2022.
 
5) 上田早智江, 真田真史, 東條かおり, 他:衛生マスク着用による皮膚性状への影響. 日本化粧品技術者会誌 57:25-34, 2023.
 
6) Mordor Intelligence Industry フェイスマスク産業レポート https://www.mordorintelligence.com/ja/industry-reports/face-mask-market
 
7) 藤林真美, 齋藤雅人, 大田香織, 他:自律神経活動を指標としたコスメティック・フェイシャルマスクの心身リラクセーション効果. 女性心身医学 13:86-93, 2008.
 
8) 日本香粧品学会編集事務局:抗シワ製品評価ガイドライン. 日本香粧品学会編集事務局. 日本香粧品学会誌 30:316-332, 2006.
 
9) 柳井久江:4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
 
10) 小山洋一:天然素材コラーゲンの機能性. 皮革科学 56:71-79, 2010.
 
11) 酒井康夫:皮膚浸透性コラーゲン・トリペプチド(CTP)の機能性と有用性. 日本写真学会誌 67:397-401, 2004.
 
12) 岡本亨:高保湿スキンケア製剤の処方設計の考え方. 日本化粧品技術者会誌 50:187-193, 2016.
 
13) 岡野由利:スキンケア化粧品のコンセプトの変化 -角層を保湿することの重要性-. 日本化粧品技術者会誌 50:91-97, 2016.
 
14) 山田秀和:最近の女性に多いシワの種類に対する傾向と対策. COSMETIC STAGE 12:1-7, 2017.
 

書評

最近チェックした商品履歴

Loading...